Lupin’s YL files for etanercept in Japan

YL Biologics, the joint venture between Lupin’s Kyowa subsidiary and Yoshindo founded in 2014, has submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its YLB113 etanercept. YL is seeking a marketing authorisation for treating moderate to severe rheumatoid arthritis and juvenile idiopathic arthritis.